08:00 , Mar 6, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Myocardial infarction (MI) Tissue inhibitor of metalloproteinases 3 (TIMP3) Pig studies suggest recombinant TIMP3-containing, biodegradable hydrogels could help reduce damage following MI. After MI,...
08:00 , Nov 21, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Dental disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Dental disease Periodontitis Chemokine CC motif ligand 22 (CCL22) Animal studies suggest CCL22-loaded microparticles could help treat periodontitis. In mouse models of...
08:00 , Nov 21, 2013 |  BC Innovations  |  Targets & Mechanisms

Getting to the root of periodontitis

Current periodontitis therapies do not target the underlying immune response that drives the disease. A team from the U.S. and Brazil is looking to change that and has shown that microparticles loaded with chemokine CC...
08:00 , Feb 4, 2013 |  BioCentury  |  Emerging Company Profile

Incanthera: Using, not targeting, MMP

Incanthera Ltd. has found a new use for a class of enzymes that are up-regulated in tumors and contribute to cancer progression. Rather than design inhibitors of matrix metalloproteinases , the biotech is instead using...
07:00 , Jun 18, 2012 |  BioCentury  |  Emerging Company Profile

Armour: Relaxin in CRPC

Armour Therapeutics Inc. 's relaxin receptor antagonists may provide a complementary hormonal therapy that can be given either with or after anti-androgen therapy in prostate cancer patients. Targeting a secondary pathway alongside an androgen pathway...
07:00 , Apr 12, 2012 |  BC Innovations  |  Targets & Mechanisms

DEL1: taking the bite out of periodontitis

An international team of researchers has used the endothelial protein DEL1 to treat periodontitis in mice. 1 Despite the therapeutic angle, the near-term utility of DEL1 is more likely to be as a diagnostic and...
01:13 , Jan 20, 2012 |  BC Extra  |  Financial News

Incanthera debuts

Newco Incanthera Ltd. (Merseyside, U.K.) raised L375,000 ($574,000) in a seed round led by the North West Fund for Biomedical, which is managed by SPARK Impact. The University of Bradford spinout is developing ICT2588 to...
07:00 , Oct 31, 2011 |  BC Week In Review  |  Clinical News

CTS-1027: Phase IIb discontinued

The trial was comparing 15, 30 and 60 mg CTS-1027 twice daily for 24 or 48 weeks plus SOC vs. SOC alone in 114 patients with chronic HCV genotype 1 infection who were null-responders to...
07:00 , Jun 23, 2011 |  BC Innovations  |  Targets & Mechanisms

A bid to revive MMP inhibitors

Matrix metalloproteinases , or MMPs, were once viewed as obvious drug targets-extracellular proteases that are selectively upregulated and play critical functional roles in many diseases. But MMP inhibitors failed in cancer trials a decade ago...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Clinical News

CTS-1027: Interim Phase II data

Interim data from 61 evaluable patients in an ongoing, single-arm, open-label, U.S. Phase II trial showed that twice-daily 15 mg CTS-1027 plus Pegasys peginterferon alfa-2a and Copegus ribavirin led to an early virologic response (EVR)...